FARS2 Antibody

What is FARS2 and why is it significant in mitochondrial research?

FARS2 (Phenylalanyl-tRNA Synthetase 2) is a mitochondrial aminoacyl-tRNA synthetase responsible for charging mitochondrial tRNA with phenylalanine, a critical step in mitochondrial protein translation. The significance of FARS2 lies in its essential role in mitochondrial function, as mutations in the FARS2 gene cause dysfunction of mitochondrial translation due to deficient aminoacylation of the mitochondrial phenylalanine tRNA . Recent research has identified that FARS2 deficiency can manifest in two distinct phenotypes: an epileptic phenotype and a spastic paraplegia phenotype, highlighting its importance in neurological function . The protein consists of four domains that work together to ensure proper aminoacylation: the N-terminal region (residues 36–83), the catalytic domain (residues 84–325), the linker region (residues 326–358), and the anticodon binding domain (residues 359–451) .

What applications are FARS2 antibodies most commonly used for?

FARS2 antibodies are utilized across multiple experimental applications in mitochondrial research. The most common applications include Western blotting (WB) for protein expression analysis, immunohistochemistry (IHC) for tissue localization studies, immunocytochemistry (ICC), immunofluorescence for cellular localization, and immunoprecipitation for protein interaction studies . Western blot analysis is particularly valuable for detecting FARS2 protein levels in mitochondrial fractions isolated from tissues such as skeletal muscle . Research data indicates that commercial antibodies against FARS2, such as those from Proteintech Group (AB_2102499), provide reliable detection when used with chemiluminescence methods (e.g., Pierce ECL plus) .

How do researchers verify the specificity of FARS2 antibodies?

Verifying antibody specificity is crucial for obtaining reliable research data. For FARS2 antibodies, researchers should implement multiple validation approaches:

• Control samples comparison: Western blot analysis comparing FARS2 protein levels between patient and control samples can verify antibody specificity. For example, in published research, similar amounts of FARS2 protein were detected in patient and control skeletal muscle samples, confirming antibody specificity .

• Knockout/knockdown validation: Tissues or cells with FARS2 knockdown or knockout can serve as negative controls.

• Recombinant protein testing: Testing antibody reactivity against purified recombinant FARS2 protein.

• Cross-reactivity assessment: Evaluating potential cross-reactivity with related aminoacyl-tRNA synthetases.

• Literature validation: Checking if the antibody has been cited in peer-reviewed publications with published figures .

What species reactivity should be considered when selecting FARS2 antibodies?

When selecting FARS2 antibodies, species reactivity is a critical consideration as it determines the experimental models that can be used. Based on available commercial products, researchers should note:

• Human reactivity: Most FARS2 antibodies are validated for human samples, which is essential for clinical studies involving patient material .

• Mouse reactivity: Many antibodies also demonstrate reactivity with mouse FARS2, facilitating translational research between human clinical samples and mouse models .

• Cross-species considerations: When studying FARS2 in non-human models, researchers should verify sequence homology and epitope conservation to ensure antibody binding.

• Multiple species validation: Some commercial antibodies are validated across multiple species, providing flexibility for comparative studies .

The specific research question should guide antibody selection, ensuring appropriate species reactivity for the experimental model.

How should researchers optimize Western blot protocols for FARS2 detection?

Optimizing Western blot protocols for FARS2 detection requires attention to several key parameters:

• Sample preparation: Mitochondrial fractions from tissue samples (particularly skeletal muscle) provide enriched FARS2 content. Isolation methods should preserve protein integrity through gentle lysis and protease inhibitors .

• Protein loading: 20-30 μg of mitochondrial protein typically yields detectable FARS2 signals.

• Gel selection: 10-12% polyacrylamide gels effectively separate FARS2 (approximately 52 kDa).

• Transfer conditions: Semi-dry transfer at 15V for 60 minutes or wet transfer at 100V for 60 minutes with methanol-containing transfer buffer.

• Blocking conditions: 5% non-fat dry milk in TBST for 1 hour at room temperature reduces background.

• Antibody dilution: Primary FARS2 antibodies typically work optimally at 1:1000 dilution (though this varies by manufacturer) .

• Detection method: Enhanced chemiluminescence (e.g., Pierce ECL plus) provides sensitive detection, with visualization using appropriate imaging software (e.g., Celvin SnapAndGo) .

• Appropriate controls: Include mitochondrial loading controls such as VDAC or ATP5A to normalize FARS2 expression.

What are the optimal conditions for immunohistochemical detection of FARS2?

For optimal immunohistochemical detection of FARS2, researchers should consider the following protocol guidelines:

• Tissue preparation: Fresh frozen sections or formalin-fixed paraffin-embedded (FFPE) tissues can be used, with antigen retrieval necessary for FFPE samples.

• Section thickness: 5-7 μm sections provide optimal results.

• Antigen retrieval: For FFPE tissues, heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes is recommended.

• Blocking: 5-10% normal serum from the same species as the secondary antibody for 1 hour reduces non-specific binding.

• Primary antibody: Anti-FARS2 antibodies validated for IHC-p applications should be incubated overnight at 4°C .

• Visualization system: HRP-conjugated secondary antibodies with DAB substrate or fluorescently-labeled secondary antibodies.

• Counterstaining: Hematoxylin for brightfield or DAPI for fluorescence microscopy.

• Controls: Include both positive controls (tissues known to express FARS2) and negative controls (omitting primary antibody).

• Mitochondrial co-localization: Co-staining with mitochondrial markers confirms specificity of the FARS2 signal.

How can researchers combine FARS2 antibody detection with functional mitochondrial assays?

Integrating FARS2 antibody detection with functional mitochondrial assays provides comprehensive insights into the relationship between FARS2 expression and mitochondrial function:

• Oxygen consumption measurements: Assess mitochondrial respiration rates using platforms like Seahorse XF Analyzer or high-resolution respirometry, correlating with FARS2 protein levels. Research has shown that fibroblasts from patients with FARS2 mutations exhibit reduced oxygen consumption rates with pyruvate, glutamate, and succinate substrates .

• OXPHOS complex activity assays: Measure activities of respiratory chain complexes spectrophotometrically and correlate with FARS2 expression. In patients with FARS2 mutations, complex I activity in fibroblasts has been found to be deficient (see Table 1 below) .

Table 1: OXPHOS Complex Activities in Patient Tissues

• Blue native PAGE with in-gel activity: Assess assembly and activity of respiratory complexes alongside FARS2 immunoblotting. This technique has revealed slightly decreased catalytic staining for complex IV and deficient assembly of complex I in patient fibroblasts .

• Aminoacylation assays: Combine Western blot detection of FARS2 with functional aminoacylation assays. High-resolution northern blotting can distinguish between aminoacylated and uncharged tRNAs, demonstrating functional consequences of FARS2 deficiency .

• Mitochondrial translation assay: Label newly synthesized mitochondrial proteins with 35S-methionine while inhibiting cytoplasmic protein synthesis, correlating translation efficiency with FARS2 protein levels .

How do mutations in FARS2 affect antibody detection and what methodological considerations are needed?

Mutations in FARS2 can impact antibody detection in several ways, requiring specific methodological considerations:

• Epitope alterations: Mutations may alter the epitope recognized by the antibody. Research has identified multiple pathogenic variants in FARS2, particularly in exons 2, 5, and 6 . When studying patient samples with known mutations, researchers should:

  • Select antibodies targeting epitopes distant from the mutation site

  • Use multiple antibodies targeting different regions of FARS2

  • Include appropriate wild-type controls

• Protein stability effects: Some mutations may affect protein stability rather than abundance. In published research, Western blot analysis revealed similar amounts of FARS2 protein in patient and control samples despite clear functional deficiencies . Therefore:

  • Combine protein detection with functional assays

  • Consider native versus denaturing conditions

  • Evaluate protein half-life through pulse-chase experiments

• Subcellular localization changes: Mutations might affect mitochondrial targeting. Researchers should:

  • Compare mitochondrial and whole-cell fractions

  • Use immunofluorescence to assess localization

  • Co-stain with mitochondrial markers

• Post-translational modifications: Altered post-translational modifications may affect antibody binding. Consider:

  • Phosphorylation-specific antibodies

  • Mass spectrometry analysis of modifications

  • Enzymatic treatments prior to immunodetection

What strategies can resolve discrepancies between FARS2 protein levels and functional impairment?

Researchers often encounter situations where FARS2 protein levels appear normal despite functional impairment, requiring sophisticated approaches to resolve these discrepancies:

• Enzyme activity assays: Measure aminoacylation activity directly using in vitro assays with recombinant FARS2 or immunoprecipitated protein. Research has demonstrated that functional validation through aminoacylation assays can reveal defects even when protein levels appear normal .

• Structural analysis: Examine how mutations affect protein structure using molecular modeling. For example, molecular modeling of patient mutations (Ala154Val, Val174del, Pro361Leu) mapped onto the crystal structure of human FARS2 revealed how these mutations could disrupt substrate binding or domain stability despite normal protein levels .

• Protein-tRNA interaction studies: Assess FARS2-tRNA binding using electrophoretic mobility shift assays or surface plasmon resonance.

• High-resolution northern blotting: Distinguish between aminoacylated and uncharged tRNAs to directly measure FARS2 function. This technique consistently detected decreased ratios between aminoacylated and deacylated forms of mitochondrial tRNA Phe in patient fibroblasts despite normal protein levels .

• Mitochondrial translation assays: Measure translation of mitochondrially-encoded polypeptides using 35S-methionine labeling. Patients with FARS2 mutations show considerable decreases in translation of mitochondrially-encoded polypeptides, with varying effects on different subunits (e.g., decreased synthesis of ND6 but normal synthesis of ND3) .

How can FARS2 antibodies be utilized in investigating the relationship between FARS2 deficiency and neurological disorders?

FARS2 antibodies are valuable tools for investigating the mechanisms connecting FARS2 deficiency to neurological disorders:

• Tissue-specific expression analysis: Compare FARS2 expression across different brain regions and peripheral tissues to understand tissue vulnerability. Immunohistochemistry with anti-FARS2 antibodies can reveal expression patterns in:

  • Cerebral cortex

  • Basal ganglia

  • Cerebellum

  • Spinal cord

  • Peripheral nerves

• Developmental expression profiling: Track FARS2 expression throughout neural development using immunohistochemistry and Western blotting.

• Patient-derived models: Analyze FARS2 expression and mitochondrial function in:

  • Patient-derived fibroblasts

  • Induced pluripotent stem cells (iPSCs)

  • iPSC-derived neurons

• Brain organoids: Evaluate FARS2 expression in 3D brain organoids from patient-derived iPSCs.

• Animal model validation: Confirm findings in animal models of FARS2 deficiency using immunohistochemistry to correlate FARS2 expression with pathology.

• Co-localization studies: Combine FARS2 antibodies with markers of:

  • Neuronal subtypes

  • Mitochondrial dynamics

  • Apoptotic pathways

  • Inflammatory responses

Research has established two distinct phenotypes associated with FARS2 deficiency: an epileptic phenotype and a spastic paraplegia phenotype . Antibody-based approaches can help elucidate why different mutations lead to these distinct presentations.

What are the most common pitfalls in FARS2 antibody experiments and how can they be addressed?

Researchers frequently encounter several challenges when working with FARS2 antibodies:

• False negatives in Western blotting:

  • Issue: Insufficient signal due to low FARS2 abundance

  • Solution: Enrich mitochondrial fractions; increase protein loading; extend exposure time; use signal enhancement systems

• Non-specific bands:

  • Issue: Multiple bands of unexpected molecular weights

  • Solution: Increase blocking time/concentration; titrate antibody concentration; include peptide competition controls; validate with siRNA knockdown

• Inconsistent results across applications:

  • Issue: Antibody works in Western blot but not IHC or vice versa

  • Solution: Verify epitope accessibility in different applications; adjust fixation conditions; try alternative antibody clones targeting different epitopes

• Batch-to-batch variability:

  • Issue: Inconsistent results with different antibody lots

  • Solution: Request lot-specific validation data; maintain reference samples for inter-lot comparisons; consider monoclonal antibodies for greater consistency

• Cross-reactivity with other aminoacyl-tRNA synthetases:

  • Issue: Antibody detects related synthetases

  • Solution: Validate specificity using recombinant proteins; include appropriate knockout controls; employ epitope mapping

• Poor mitochondrial localization:

  • Issue: Diffuse rather than mitochondrial staining

  • Solution: Optimize fixation conditions; use appropriate permeabilization; co-stain with established mitochondrial markers

How should researchers validate FARS2 antibody specificity in disease models with altered mitochondrial morphology?

Validating FARS2 antibody specificity in disease models with altered mitochondrial morphology requires specialized approaches:

• Genetic controls: Implement CRISPR/Cas9-mediated FARS2 knockout or knockdown as definitive negative controls.

• Peptide competition assays: Pre-incubate antibody with excess immunizing peptide to confirm specificity.

• Multiple antibody validation: Use antibodies targeting different FARS2 epitopes and compare staining patterns.

• Super-resolution microscopy: Employ techniques like STORM or STED to verify mitochondrial localization despite altered morphology.

• Quantitative co-localization analysis: Calculate Pearson's correlation coefficient between FARS2 and established mitochondrial markers.

• Western blot with subcellular fractionation: Compare FARS2 levels in mitochondrial, cytosolic, and nuclear fractions.

• Mass spectrometry validation: Identify proteins in immunoprecipitated samples to confirm FARS2 specificity.

• Orthogonal detection methods: Combine antibody-based detection with mRNA localization (e.g., RNA FISH) or tagged constructs.

• Functional rescue experiments: Demonstrate restoration of normal staining pattern after complementation with wild-type FARS2.

What quantitative approaches should be used to correlate FARS2 expression with mitochondrial dysfunction severity?

To establish meaningful correlations between FARS2 expression and mitochondrial dysfunction severity, researchers should employ rigorous quantitative approaches:

• Standardized Western blot quantification:

  • Use mitochondrial loading controls (e.g., VDAC, TOM20)

  • Implement linear range detection

  • Employ replicate biological and technical samples

  • Apply appropriate statistical analysis

• Automated image analysis in immunohistochemistry/immunofluorescence:

  • Develop consistent thresholding protocols

  • Quantify signal intensity relative to mitochondrial markers

  • Assess mitochondrial morphology parameters (area, perimeter, circularity)

  • Measure co-localization coefficients

• Correlation with biochemical assays:

  • Oxygen consumption rates (OCR)

  • ATP production

  • Membrane potential measurements

  • ROS production

• Multi-parameter analysis:

  • Implement principal component analysis

  • Develop severity indices combining multiple parameters

  • Use machine learning to identify patterns

• Single-cell correlation analyses:

  • Correlate FARS2 expression with mitochondrial function at the single-cell level

  • Account for cellular heterogeneity

• Longitudinal assessments:

  • Track FARS2 expression and mitochondrial function over time

  • Correlate with disease progression

Research has shown that decreased aminoacylation of mt-tRNA Phe correlates with impaired mitochondrial translation rates, with different degrees of impairment across mitochondrial subunits . This highlights the importance of quantitative approaches that can capture the complexity of mitochondrial dysfunction.

How can FARS2 antibodies be integrated with new mitochondrial imaging technologies?

Integration of FARS2 antibodies with cutting-edge mitochondrial imaging technologies offers exciting research opportunities:

• Live-cell imaging approaches:

  • Using cell-permeable FARS2 antibody fragments

  • Combining with mitochondrial-targeted fluorescent proteins

  • Correlating FARS2 dynamics with mitochondrial movement and fusion/fission events

• Super-resolution microscopy:

  • Applying STED, STORM, or PALM techniques for nanoscale localization

  • Resolving FARS2 distribution within mitochondrial subcompartments

  • Examining co-localization with translation machinery components

• Multi-color FRET applications:

  • Measuring protein-protein interactions between FARS2 and tRNA or other translation factors

  • Detecting conformational changes in FARS2 during aminoacylation

• Cryo-electron tomography:

  • Combining with immunogold labeling for ultrastructural localization

  • Contextualizing FARS2 position within mitochondrial translation complexes

• Expansion microscopy:

  • Achieving super-resolution with standard confocal microscopes

  • Visualizing FARS2 distribution in relation to mitochondrial cristae

• Correlative light and electron microscopy (CLEM):

  • Linking FARS2 fluorescence data with ultrastructural information

  • Precisely localizing FARS2 within mitochondrial compartments

• Multi-spectral imaging:

  • Simultaneously tracking multiple mitochondrial components

  • Creating comprehensive spatial maps of the mitochondrial translation machinery

What role might FARS2 antibodies play in developing therapeutic approaches for mitochondrial translation disorders?

FARS2 antibodies could contribute significantly to therapeutic development for mitochondrial translation disorders:

• Target validation and screening:

  • Confirming therapeutic targets in the mitochondrial translation pathway

  • Screening for compounds that modulate FARS2 expression or activity

  • Evaluating off-target effects on related aminoacyl-tRNA synthetases

• Biomarker development:

  • Establishing FARS2 protein levels as predictive or prognostic biomarkers

  • Monitoring treatment response in clinical trials

  • Stratifying patients for personalized therapeutic approaches

• Therapeutic protein delivery:

  • Tracking biodistribution of therapeutic FARS2 proteins

  • Confirming mitochondrial localization of delivered proteins

  • Assessing stability and half-life of therapeutic proteins

• Gene therapy monitoring:

  • Distinguishing endogenous from exogenous FARS2 expression

  • Quantifying spatial and temporal expression patterns after gene delivery

  • Correlating expression with functional recovery

• Drug mechanism studies:

  • Investigating how compounds affect FARS2 protein levels or localization

  • Examining effects on protein-protein or protein-tRNA interactions

  • Assessing restoration of aminoacylation activity

• Theranostic applications:

  • Developing FARS2 antibody-drug conjugates for targeted delivery

  • Creating imaging agents to monitor disease progression

The development of therapeutic approaches for FARS2-related disorders remains in early stages, but understanding the two distinct phenotypes (epileptic and spastic paraplegia) provides important context for developing targeted interventions .

How can integrative multi-omics approaches incorporate FARS2 antibody-based data to better understand mitochondrial disease mechanisms?

Integrating FARS2 antibody-based data with multi-omics approaches provides a comprehensive framework for understanding mitochondrial disease mechanisms:

• Proteomics integration:

  • Correlate FARS2 protein levels with global mitochondrial proteome changes

  • Identify compensatory mechanisms in response to FARS2 deficiency

  • Map post-translational modifications affecting FARS2 function

• Transcriptomics correlation:

  • Link FARS2 protein levels with mitochondrial and nuclear gene expression changes

  • Identify retrograde signaling pathways activated by FARS2 deficiency

  • Discover potential therapeutic targets through expression pattern analysis

• Metabolomics analysis:

  • Correlate FARS2 expression with metabolic alterations

  • Identify biomarkers of mitochondrial dysfunction

  • Track therapeutic responses at the metabolite level

• Functional genomics integration:

  • Combine FARS2 expression data with genome-wide CRISPR screens

  • Identify genetic modifiers of FARS2-related phenotypes

  • Discover synthetic lethal interactions for therapeutic targeting

• Systems biology modeling:

  • Develop predictive models incorporating FARS2 expression data

  • Simulate effects of therapeutic interventions

  • Identify critical nodes in mitochondrial translation networks

• Single-cell multi-omics:

  • Analyze FARS2 expression and function at single-cell resolution

  • Identify cellular subpopulations with differential vulnerability

  • Track disease progression at unprecedented resolution

Research has demonstrated that the relationship between FARS2 mutations and phenotype is complex, with no clear correlation between mutation location and disease presentation . Integrated multi-omics approaches could help elucidate the factors determining which phenotype (epileptic or spastic paraplegia) manifests in patients with FARS2 deficiency.